Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report) during the second quarter, Holdings Channel reports. The institutional investor purchased 159,108 shares of the company’s stock, valued at approximately $3,265,000.
Several other institutional investors have also recently made changes to their positions in FLGT. BlackRock Inc. bought a new stake in shares of Fulgent Genetics in the second quarter valued at about $46,922,000. Northwestern Mutual Wealth Management Co. grew its holdings in Fulgent Genetics by 2,984,354.9% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,522,072 shares of the company’s stock worth $39,985,000 after acquiring an additional 1,522,021 shares in the last quarter. RTW Investments LP purchased a new position in Fulgent Genetics during the 4th quarter valued at about $18,521,000. JPMorgan Chase & Co. raised its holdings in shares of Fulgent Genetics by 767.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 299,014 shares of the company’s stock valued at $6,758,000 after purchasing an additional 264,524 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Fulgent Genetics by 89.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 348,533 shares of the company’s stock valued at $9,156,000 after purchasing an additional 164,535 shares in the last quarter. Hedge funds and other institutional investors own 48.06% of the company’s stock.
Insider Buying and Selling at Fulgent Genetics
In other news, COO Jian Xie sold 2,146 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $38,391.94. Following the completion of the sale, the chief operating officer owned 367,605 shares of the company’s stock, valued at $6,576,453.45. This trade represents a 0.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Hanlin Gao sold 1,688 shares of the business’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $30,198.32. Following the transaction, the insider owned 990,374 shares in the company, valued at approximately $17,717,790.86. This trade represents a 0.17% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 5,966 shares of company stock worth $111,038 over the last ninety days. Corporate insiders own 36.18% of the company’s stock.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on FLGT
Fulgent Genetics Stock Performance
FLGT stock opened at $19.61 on Friday. The firm has a market cap of $539.47 million, a price-to-earnings ratio of -6.95 and a beta of 0.90. The firm has a 50-day simple moving average of $19.63 and a two-hundred day simple moving average of $18.15. Fulgent Genetics, Inc. has a one year low of $13.46 and a one year high of $31.04.
Fulgent Genetics (NASDAQ:FLGT – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.12). The firm had revenue of $85.39 million during the quarter, compared to analysts’ expectations of $94.00 million. Fulgent Genetics had a negative return on equity of 4.93% and a negative net margin of 26.05%.Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. As a group, equities analysts predict that Fulgent Genetics, Inc. will post -3.48 earnings per share for the current fiscal year.
Fulgent Genetics Company Profile
Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.
Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.
Featured Articles
- Five stocks we like better than Fulgent Genetics
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Want to see what other hedge funds are holding FLGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulgent Genetics, Inc. (NASDAQ:FLGT – Free Report).
Receive News & Ratings for Fulgent Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
